Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease

A Multi-Center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients With Fabry Disease

The purpose of this study is to compare the safety and effectiveness of various doses of Replagal in patients with cardiomyopathy due to Fabry disease.

Study Overview

• Status: Completed
• Conditions: Fabry Disease
• Intervention / Treatment: Biological: Replagal

Detailed Description

Fabry disease is an inherited, metabolic disease caused by mutations in the GALA gene. Patients with Fabry disease accumulate a complex glycosphingolipid named globotriaosylceramide (Gb3) in various tissues and organs. All organs are affected in Fabry disease but the majority of the morbidity and mortality are caused by cardiac, renal and neurological dysfunction. Accumulation of Gb3 in the heart causes hypertrophic cardiomyopathy, valvular abnormalities, arrhythmias and infarctions. Replagal has been shown to reduce Gb3 from key tissues and organs, and stabilize renal function in patients with Fabry disease. Evidence suggests that Replagal reduces left ventricular mass (LVM) and improves midwall fractional shortening (MFS) of the heart. Left ventricular hypertrophy is a major cause of morbidity and mortality in patients with Fabry disease.

This is a study of the safety and effectiveness of 3 dosing regimens of Replagal in adult patients with left ventricular hypertrophy due to Fabry disease.

The primary objective of the study is to compare the effects of 2 dosing regimens of Replagal (0.2 mg/kg IV every other week and 0.2 mg/kg IV weekly) on the reduction of left ventricular mass as measured by echocardiography.

The secondary objectives of this study are to compare the effects of 2 dosing regimens of Replagal (0.2 mg/kg IV every other week and 0.2 mg/kg IV weekly) on each of the following: exercise tolerance; improvement in disease-specific quality of life in heart failure patients; improvement of heart failure symptoms; magnitude of reduction in Gb3; rate of decline in renal function and improvement in the severity of proteinuria/albuminuria; and safety.

An alternative treatment regimen of 0.4 mg/kg Replagal IV weekly will also be explored but without formal comparison to the 0.2 mg/kg regimens. The investigation of the safety and efficacy of the 0.4 mg/kg IV weekly regimen is a secondary objective of this study.

• Study Type: Interventional
• Enrollment (Actual): 44
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • Victoria
    • Parkville, Victoria, Australia, 3052
      • The Royal Melbourne Hospital
• Czechia
  • Prague, Czechia, 128 OO
    • The Charles University Hospital
• Finland
  • Turku, Finland, FI-20520
    • Turku University Central Hospital
• Paraguay
  • Asuncion, Paraguay
    • Gobemador Irala y Coronel Lopez - Barrio Sojania
• Poland
  • Krakow, Poland, 31-066
    • Szpital Uniwersytecki w Krakowie
  • Warsaw, Poland, 04-628
    • Instytut Kardiologii
• Slovenia
  • Slovenj Gradec, Slovenia, SI 2380
    • General Hospital Slovenj Gradec
• United Kingdom
  • Salford, United Kingdom, M6 8HD
    • Salford Royal NHS Foundation Trust
• United States
  • Arizona
    • Tucson, Arizona, United States, 85719
      • AKDHC Tucson Access Center
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • University of Iowa Hospitals and Clinics
  • New York
    • New York, New York, United States, 10016
      • New York Unversity School of Medicine
  • Virginia
    • Springfield, Virginia, United States, 22152
      • O & O Alpan, LLC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• >18 years-old;
• Male:Fabry disease confirmed by deficiency of alfa galactosidase A activity OR Female:Fabry disease confirmed by a mutation of the alfa galactosidase A gene;
• ERT-naïve;
• LVM/h > 50g/m2.7 for males and >47 g/m2.7 for females;
• Negative pregnancy test at enrollment and contraception use required throughout study for female patients;
• Signed informed consent;

Exclusion Criteria:

• Class IV heart failure;
• Clinically significant hypertension;
• Hemodynamically significant valvular stenosis or regurgitation;
• Morbid obesity;
• Known autosomal dominant sarcoplasmic contractile protein gene mutation;
• Treatment with any investigational drug or device within the 30 days;
• Unable to comply with the protocol as determined by the Investigator;
• Positive for hepatitis B, hepatitis C or HIV

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Replagal 0.2 mg/kg, IV, every other week; Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every other week for 52 weeks.	Biological: Replagal; Intravenous (IV) infusion for 12 months; Other Names: algasidase alfa
Active Comparator: Replagal 0.2 mg/kg, IV, weekly; Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every week for 52 weeks.	Biological: Replagal; Intravenous (IV) infusion for 12 months; Other Names: algasidase alfa
Active Comparator: Replagal 0.4 mg/kg, IV, weekly; Patients randomized to receive Replagal 0.4 mg/kg via intravenous infusion every week for 52 weeks.	Biological: Replagal; Intravenous (IV) infusion for 12 months; Other Names: algasidase alfa

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline to Month 12 in Left Ventricular Mass Indexed to Height (LVMI)	Left ventricular mass (LVM) was measured through echocardiography.	Baseline, Month 12 (Week 53)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline to Month 12 in Maximal Oxygen Consumption (VO2 Max) at Peak Exercise	Exercise tolerance as measured by VO2 max at peak exercise using the standard exponential exercise protocol (STEEP).	Baseline, Month 12 (Week 53)
Change From Baseline to Month 12 in Distance Walked in 6-Minute Walk Test (6MWT)	Exercise tolerance using the 6MWT was measured as the total distance walked in 6 minutes.	Baseline, Month 12 (Week 53)
Change From Baseline to Month 12 in the Minnesota Living With Heart Failure Questionnaire (MLHF-Q) Summary Score	Quality of life (QoL) was evaluated using the MLHF-Q, version 2. The questionnaire is designed to assess the degree to which heart failure symptoms affect a patient's daily life. The summary score ranges from 0 to 105, with a score of 105 representing the highest adverse impact on a patient's QoL.	Baseline, Month 12 (Week 53)
Change From Baseline to Month 12 in New York Heart Association (NYHA) Functional Class	The NYHA functional classification system relates symptoms to everyday activities and the patient's quality of life. NYHA Classification - The Stages of Heart Failure: Class I (Mild): No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea (shortness of breath). Class II (Mild): Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea. Class III (Moderate): Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV (Severe): Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased.	Baseline, Month 12 (Week 53)
Change From Baseline to Month 12 in Plasma Globotriaosylceramide (GB3)		Baseline, Month 12 (Week 53)
Change From Baseline to Month 12 in Estimated Glomerular Filtration Rate (eGFR)	Renal function was assessed by an evaluation of change from baseline to Month 12 in eGFR as calculated using the Modification of Diet for Renal Disease (MDRD) equation.	Baseline, Month 12 (Week 53)
Change From Baseline to Month 12 in Urinary Albumin/Creatinine (A/Cr) Ratio		Baseline, Month 12 (Week 53)
Safety Evaluation	Adverse events were collected throughout the study, from the time of informed consent to approximately 30 days post-final infusion.	56 Weeks

Collaborators and Investigators

• Sponsor: Shire

Publications and helpful links

General Publications

• Malek LA, Chojnowska L, Spiewak M, Klopotowski M, Misko J, Petryka J, Milosz B, Ruzyllo W. Cardiac magnetic resonance imaging in patients with Fabry's disease. Kardiol Pol. 2010 Aug;68(8):929-34.

Study record dates

Study Major Dates

• Study Start (Actual): December 29, 2008
• Primary Completion (Actual): June 1, 2012
• Study Completion (Actual): July 5, 2012

Study Registration Dates

• First Submitted: March 18, 2009
• First Submitted That Met QC Criteria: March 18, 2009
• First Posted (Estimate): March 19, 2009

Study Record Updates

• Last Update Posted (Actual): June 9, 2021
• Last Update Submitted That Met QC Criteria: May 14, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Metabolic Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Metabolism, Inborn Errors; Lysosomal Storage Diseases; Lipid Metabolism Disorders; Brain Diseases, Metabolic; Brain Diseases, Metabolic, Inborn; Sphingolipidoses; Lysosomal Storage Diseases, Nervous System; Cerebral Small Vessel Diseases; Lipidoses; Lipid Metabolism, Inborn Errors; Fabry Disease
• Other Study ID Numbers: TKT028; 2007-005543-22 (EudraCT Number)